RxDoctor Payments DataLook up a doctor →

Jorge Diaz Castro, MD

Hematology & Oncology · Huntsville, ALNPI 1558517987

Payments from drug & device makers

$75,313in general payments, 2019–2025

Across 706 payments — averaging $106.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$20K
  • Sobi, Inc$18K
  • Morphosys AG$12K
  • Regeneron$6K
  • Amgen$6K
  • Novartis$1K
  • plus $12K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation33$19,975
Sobi, Inc4$17,538
Morphosys AG5$11,577
Regeneron6$6,413
Amgen27$6,180
Novartis73$1,249
AstraZeneca(2 entities)48$1,033
Eli Lilly1$895
Merck44$854
Pfizer47$699
E.r. Squibb & Sons, L.L.C.50$687
Johnson & Johnson25$524
Seagen Inc.27$502
Gilead(2 entities)18$443
Beigene USA, Inc.10$433
Welch Allyn1$432
Eisai Inc.24$372
Bristol Myers Squibb15$368
Daiichi Sankyo Inc.16$318
Takeda Pharmaceuticals U.S.A., Inc.12$290
Sanofi14$288
GSK8$266
Pharmacyclics LLC, An Abbvie Company17$236
AbbVie12$215
Lilly USA, LLC16$211
Bayer13$197
Boehringer Ingelheim9$183
Astellas Pharma US Inc11$172
Secura Bio, Inc.2$165
Genentech USA, Inc.10$163
Genmab U.S., Inc.2$160
Beone Medicines USA, Inc.8$151
Puma Biotechnology, Inc.3$122
Ipsen Biopharmaceuticals, Inc5$121
Stemline Therapeutics Inc.5$120
Exelixis Inc.5$116
Array Biopharma Inc6$115
Octapharma USA, Inc.2$115
Regeneron Healthcare Solutions, Inc.4$106
Blueprint Medicines Corporation4$101
Jazz Pharmaceuticals Inc.4$93
Pharmaessentia USA Corporation2$60
Mirati Therapeutics, Inc.3$58
Boston Scientific1$49
Coherus Oncology, Inc.2$48
Aurobindo Pharma USA, Inc.3$47
Agios Pharmaceuticals, Inc.3$47
Dova Pharmaceuticals3$45
Tempus AI, Inc2$44
Tersera Therapeutics LLC2$41
Iovance Biotherapeutics, Inc.2$41
Bard Peripheral Vascular, Inc.1$37
Servier Pharmaceuticals LLC2$36
AVEO Pharmaceuticals, Inc.2$35
Karyopharm Therapeutics Inc.2$33
ADC Therapeutics America, Inc.2$33
Acrotech Biopharma Inc.2$32
Sun Pharmaceutical Industries Inc.1$31
Kyowa Kirin, Inc.2$31
Dendreon Pharmaceuticals LLC2$30

How this compares

$75,313 in reported general payments places this provider in the 65th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$4,003,815
Medicare patients
783
Services billed
152,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Huntsville

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →